| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
ZUSDURI® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth |
| 20 Aug 2026 |
8-K: Other Events
On August 18, 2026, UroGen Pharma Ltd. (“the Company”), through its wholly owned subsidiary UroGen Pharma, Inc. (“UroGen U.S.”), entered into an Option and Research License Agreement (the “Option Agreement”) with IntraGel Therapeutics, L... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
ZUSDURI® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth |
| 23 Jun 2026 |
8-K: Material Modification to Rights of Security Holders; Departure/Election of Directors or Officers; Compensation +1 more
In these Articles, unless the context requires otherwise, the following capitalized terms shall have the meanings set opposite them: |
| 02 Jun 2026 |
8-K: Other Events
On June 2, 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. (collectively, “the Company”) issued a press release announcing that the Company entered into a settlement and license agreement (the “Agreement”) with Teva Pharmaceuticals, Inc.... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecti... |
| 02 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) ... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial |
| 27 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) |
| 03 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 Jun 2025 |
8-K: Other Events
On June 12, 2025, the U.S. Food and Drug Administration (“FDA”) approved ZUSDURI™ (mitomycin), formerly known as UGN-102, a sustained-release gel formulation of mitomycin for the treatment of adults with recurrent low-grade intermediate ... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July |
| 10 Mar 2025 |
8-K: Results of Operations and Financial Condition
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 |
| 20 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
On February 14, 2025 (the “Closing Date”), UroGen Pharma Ltd. (the “Company”) and UroGen Pharma, Inc. (“Purchaser”) entered into an Asset Purchase Agreement (the “Agreement”) with IconOVir Bio, Inc. (“IconOVir”), pursuant to which Purcha... |
| 14 Jan 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Developing Innovative Medicines to Treat Urothelial Cancers January 2025 |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 |
| 09 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
This Executive Employment Agreement (the “Agreement”), is hereby made this 7th day of October, 2024, between UroGen Pharma, Inc., a wholly owned subsidiary (the “Subsidiary”) of UroGen Pharma Ltd. (the “Parent”, and the Subsidiary and th... |
| 24 Sep 2024 |
8-K: Creation of a Direct Financial Obligation
As previously reported, on March 13, 2024, UroGen Pharma Ltd. (the “Company”), UroGen Pharma, Inc., as the borrower (the “Borrower”), and certain direct and indirect subsidiaries of the Company party thereto from time to time, as guarant... |
Loading...